RISA Labs ₹100 Crore Success: The AI Startup Simplifying Cancer Treatment
One of the hardest-to-handle areas of health care is cancer treatment, and it’s not just the disease that presents challenges; it’s the complicated administrative hurdles as well. Insurance approvals, paperwork, and treatment coordination can take a significant amount of time for doctors and healthcare providers, making it a distraction from providing comprehensive patient care. A young healthcare AI start-up company, RISA Labs, is here to change that.
The Palo Alto-based startup has raised a total of $11.1 million (more than ₹100 crore) in its Series A round, a significant achievement. The investment will support expanding the company’s AI-driven oncology platform throughout the United States and help cancer care providers cut administrative waste and enhance access to life-saving care. The investment also underscores the rising confidence of investors in industry-specific AI tools and solutions.
Company Overview
| Particular | Details |
|---|---|
| Company Name | RISA Labs |
| Industry | Healthcare AI (HealthTech) |
| Headquarters | Palo Alto, California, USA |
| Founded | June 2024 |
| Founders | Kshitij Jaggi and Kumar Shivang |
| Latest Funding | $11.1 Million (Over ₹100 Crore) Series A |
| Lead Investors | Cencora Ventures and Optum Ventures |
| Other Investors | Oncology Ventures, z21 Ventures, VentureForGood (John Simon) |
| Flagship Product | BOSS – AI-Powered Operating System for Oncology Workflows |
| Business Model | AI-driven workflow automation for cancer clinics, health systems, and speciality pharmacies |
| Target Market | Oncology (Cancer Care) and Healthcare Providers in the United States |
| Primary Focus | Simplifying complex oncology workflows, prior authorisations, insurance verification, and administrative tasks using AI |
RISA Labs raises over ₹100 Crore in Series A funding
RISA Labs has successfully raised $11.1 million (more than ₹100 crore) in its Series A funding round. Cencora Ventures and Optum Ventures, two leading investors with a clear focus on healthcare innovation, were co-lead investors for the investment.
The round also included investors Oncology Ventures, z21 Ventures and John Simon on the VentureForGood platform, who are both co-founders of General Catalyst.
The newly raised money will be dedicated to speeding up the rollout of RISA’s AI platform in cancer clinics, health systems, speciality pharmacies, and infusion centres across the U.S.
The Story Behind RISA Labs
Kshitij Jaggi and Kumar Shivang established RISA Labs in June 2024. The company’s headquarters are in Palo Alto, California, but the founders have strong Indian connections and are dedicated to resolving one of the most critical operational challenges in the healthcare sector.
The founders decided against creating a general-purpose AI system and selected oncology, where treatment processes are among the most complex in today’s medical practice. They have a straightforward but profound goal of letting doctors focus more on patient care and AI to do the repetitive administrative work.
Meet BOSS: RISA’s AI Console for Oncology
The company’s flagship product is its AI-powered operating system, specifically for cancer care, named BOSS. Multiple phases of approvals, insurance verifications, treatment planning, documentation and communication between various healthcare providers are part of cancer treatment. These tasks can result in delays that may affect patient care.
BOSS automates these complex workflows with several AI agents that perform:
- Patient access management
- Benefits verification
- Prior authorization
- Workflows for insurance and payers.
- Administrative documentation
Rather than being burdened by the manual process, healthcare organisations can benefit from BOSS and minimise delays, helping clinicians provide high-quality patient care.
Why Oncology Needs AI
Oncology is one of the most complicated medical specialities. Each patient can have unique combinations of treatments, multiple drugs, evolving insurance policies, and disease-specific treatment plans. These variables can be difficult to manage, and doing so takes a lot of time and adds to the risk of delays.
A Vertical AI Strategy That Stands Out
Approval delays or paperwork can cause delays in treatment, which can cause unnecessary stress for both the patient and healthcare providers. RISA Labs hopes to fix this “administrative toxicity” by first introducing intelligent AI automation that can help healthcare teams without taking the place of clinical decision-making.
The Rising Tide of Vertical AI: What Is It and How Can It Transform Your Business? A lot of AI firms are working on all-encompassing solutions across several industries. RISA Labs has instead chosen to play in just one high-value healthcare segment: oncology.
This unique approach enables the company to develop AI models that address the distinct workflows, payer guidelines, treatment processes, and documentation needs in cancer care. The industry’s experts have become convinced that these vertical, specialised platforms will be the way forward in healthcare AI, rather than generic AI platforms.
Strong Investor Confidence
Investors in Series A show their faith in RISA Labs’ vision. Cencora Ventures and Optum Ventures are well entrenched in the healthcare distribution, insurance and provider sectors. As a result, RISA Labs is not only getting funding, but also strategic partnerships that can help to drive adoption.
The startup’s partnership with Oncology Ventures, z21 Ventures and VentureForGood further solidifies its standing in the swiftly expanding healthcare-AI sector.
How the Funding Will Be Used
The newly raised capital will be used to help expand the company’s operations in the United States.
It has several priorities to focus on; these are the main ones:
- Enlarging coverage in cancer clinics
- Building Healthy Collaboratives with health systems.
- Supporting speciality pharmacies and infusion centres
- Strengthening the capabilities of AI in the BOSS platform
- Scaling distribution nationwide
The investments are projected to enable more healthcare organisations to automate more complex workflows and implement efficiencies in oncology care.
The Growing Opportunity for Healthcare AI
Healthcare AI startup RISA Labs has raised $11.1 Mn (over INR 100 Cr) in a Series A funding round co-led by US-based VC firms Cencora Ventures and Optum Ventures. Besides, investors like Oncology Ventures, z21 Ventures, and General Catalyst cofounder John Simon via VentureForGood… pic.twitter.com/kCpJ1yIkcS
— Inc42 (@Inc42) January 15, 2026
While artificial intelligence has several promising areas in healthcare, one of the greatest is in the reduction of administrative functions.
Physicians spend hours a day documenting, checking on insurance details and paperwork. AI frees up health care professionals’ time to focus on patient care by streamlining repetitive tasks.
RISA Labs is a new breed of health care startups that address operational issues rather than replace doctors, and thus represents an AI tool that can be a great help rather than a hindrance.
What does this imply for the future?
The success of RISA Labs is a broader trend in the AI industry. Rather than developing products that are a jack-of-all-trades, startups are increasingly developing very specific platforms for specific sectors.
As RISA Labs progresses with its successful expansion, its technology may become a vital component of oncology care, enabling hospitals to minimise delays, optimise workflows, and enhance the patient and physician experience.
The company has a clear mission and is supported by strong investors, positioning it well to become one of the top AI innovators in healthcare.
Frequently Asked Questions (FAQs)
How much money has been raised by RISA Labs?
RISA Labs has raised a total amount of $11.1 million (more than ₹100 crore) in its Series A funding round.
Who created RISA Labs?
In June 2024, the company was established by Kshitij Jaggi and Kumar Shivang.
What is BOSS?
BOSS is the artificial intelligence-driven operating system from RISA Labs that automates complex oncology workflows, including patient access, prior authorisation, and insurance verification.
Who was the lead for the Series A round?
Cencora Ventures and Optum Ventures were the co-leaders of the funding round.
What will RISA Labs do with the new money?
The investment will be used to further the company’s expansion of its AI platform nationwide in cancer clinics, health systems, speciality pharmacies and infusion networks.
Final Words
RISA Labs is proving that artificial intelligence can do much more than automate routine tasks. By focusing on the complex administrative challenges of oncology, the startup is helping healthcare providers spend less time on paperwork and more time caring for patients. Its successful ₹100 crore+ Series A funding reflects growing confidence in specialised AI solutions that address real-world healthcare problems.
